Zelira Therapeutics Limited (ZLD.AX)
| Previous close | 1.0500 |
| Open | 1.0500 |
| Bid | 1.0500 x 14831600 |
| Ask | 1.0700 x 5161300 |
| Day's range | 1.0500 - 1.0500 |
| 52-week range | 0.9000 - 5.2503 |
| Volume | |
| Avg. volume | 5,278 |
| Market cap | 10.056M |
| Beta (5Y monthly) | 1.37 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.5050 |
| Earnings date | 21 Feb 2023 - 27 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 11.70 |
- PR Newswire
Zelira Therapeutics Launches ZYRAYDI™ B2B Technology to Create Pharma-grade Cannabis Capsules & Tablets for Global Markets
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a global leader in the research, development and commercialization of clinically validated cannabinoid medicines, is pleased to announce the launch of ZYRAYDI™, its patented, licensable technology for the future of the medical cannabis industry.
- PR Newswire
Zelira's Zenivol™, the World's First Clinically Validated Cannabinoid Medication for Insomnia, Achieves Regulatory Approval in Germany
Zelira Therapeutics Ltd (ASX: ZLD, OTC-QB: ZLDAF), a global leader in the research, development and commercialization of clinically validated cannabinoid medicines, is pleased to announce that its groundbreaking insomnia medication Zenivol™ has achieved formal approval from German regulatory authority BfArM to launch in the German medical cannabis market.
- Simply Wall St.
We're Keeping An Eye On Zelira Therapeutics' (ASX:ZLD) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although...
